CClinicalTrials.gg
CompletedNCT02460900Updated Mar 13, 2025Results posted

Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke

A Phase 3 interventional study of Varenicline and Positively Smoke Free in Smoking and HIV, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by University of Maryland, Baltimore · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV/AIDS who smoke. Results of this study will provide crucial, real world evidence of the best way for healthcare providers to help smokers living with HIV/AIDS quit smoking.

Read the detailed description

The study used a factorial design to randomize participants into 4 conditions: (1) Varenicline (12 weeks) + Positively Smoke Free (PSF) (8 weeks); (2) Varenicline (12 weeks) + Standard of Care (brief advice to quit); (3) Placebo (12 weeks) + Positively Smoke Free (8 weeks); and (4) Placebo (12 weeks) + Standard of Care. The primary outcome was the 7-day point prevalence abstinence (PPA) (\<10mm) at 36 weeks.

The specific aims of our proposal are:

Primary Aim 1: Compare varenicline to placebo on rates of 7-day point prevalence abstinence (PPA) at 36 weeks in smokers with HIV/AIDS. We hypothesize that rates of smoking abstinence at week 36 will be higher in those treated with varenicline compared to placebo.

Primary Aim 2: Compare Positively Smoke Free to low intensity, brief counseling on rates of 7-day PPA at 36 weeks in smokers with HIV/AIDS. We hypothesize that rates of smoking abstinence at week 36 will be higher in those treated with Positively Smoke Free compared to brief counseling.

Primary Aim 3: Compare Positively Smoke Free + varenicline to the other two study conditions outlined above on rates of 7-day PPA in smokers with HIV/AIDS at 36 weeks. We hypothesize the effect of PSF with varenicline is greater than the effect of PSF or varenicline alone.

Exporatory Aim: Explore the effect of successful cessation/smoking abstinence on levels of cardiac specific biomarkers, nicotine biomarkers, generalized markers of inflammation, lipids, coagulation and monocyte/macrophage activation.

02

Conditions studied

03

In context

Acquired Immunodeficiency Syndrome

2,040 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 272 are open to participants now.

This study's enrollment of 184 is above the median of 105 across 1,543 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 687 studies on the registry; 130 are open to participants now.

Of its 90 completed or terminated interventional studies of FDA-regulated products, 63 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Study Inclusion Criteria:

  1. Confirmed chart diagnosis of a HIV and receiving HIV treatment at the participating HIV clinic.
  2. Age 18 years or older.
  3. Currently self-report smoking 10 cigarettes per day
  4. Motivation to quit within the next 6 months (score 5-8 on the Abrams and Briener Readiness to Quit Ladder);
  5. Does not meet criteria for current Diagnostic Statistical Manual (DSM) 5 moderate or severe alcohol use disorder or moderate or severe substance use disorder as established by the Mini Neuropsychiatric Interview (MINI) drug and alcohol sections (in the last 3 months)
  6. Able to read and speak English
  7. Willingness and ability to provide informed consent to participate.

Study Exclusion Criteria:

The exclusion criteria are designed to maximize safety by minimizing drug interactions or worsening pre-existing comorbid psychiatric or medical conditions:

  1. Current suicidal thoughts or ideation (past week); recent suicidal thoughts or ideation (past 6 months) or recent suicide attempt (past 6 months) as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).
  2. Previous allergic reaction or hypersensitivity to Varenicline (by participant report ever in lifetime)
  3. Pregnant, nursing, or becoming pregnant during the study (pregnancy test).
  4. Current use of any medication that would interfere with the protocol in the opinion of Medically Accountable Physician including use of bupropion targeting nicotine dependence
  5. Moderate to severe renal impairment (\< 30 mL/min)--As determined by a physician assessment, chart review or thru blood work
  6. Unstable cardiovascular disease (myocardial infarction within past year, uncontrolled arrhythmia, uncontrolled angina, uncontrolled congestive heart failure, electrocardiogram abnormality with QTC > 500 msec, cerebrovascular event within past year). (As determined by a physician assessment, chart review and/or EKG)
  7. Meets criteria for dementia by scoring below 10 on the Hopkins HIV Dementia Scale. This criterion is included to ensure the sample consists of participants who are cognitively able to engage in the study procedures
  8. Scores \<5 ppm of expired carbon monoxide (CO) on the Smokelyzer
  9. The study physician believes that the individual is not medially stable enough to participate in the study. This exclusion will be based on a review of the individual's past medical history and current medical status.
  10. Recent use of Varenicline (by participant report in the past 3 months)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (actual)

Study arms

  • Active comparator
    Varenicline and Standard of Care

    Participants will receive varenicline and standard of care

    Drug: Varenicline · Behavioral: Standard of Care

  • Placebo comparator
    Placebo and Standard of Care

    Participants will receive placebo and standard of care

    Drug: Placebo · Behavioral: Standard of Care

  • Active comparator
    Positively Smoke Free and Placebo

    Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo

    Behavioral: Positively Smoke Free · Drug: Placebo

  • Active comparator
    Positively Smoke Free and Varenicline

    Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline

    Drug: Varenicline · Behavioral: Positively Smoke Free

Interventions

  • DrugVarenicline
  • BehavioralPositively Smoke Free
  • DrugPlacebo
  • BehavioralStandard of Care
06

What researchers measure

Primary outcomes

  1. Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks

    7-day point-prevalence abstinence based onno self-reported tobacco use (not even a puff) during the 7 days preceding the assessment and a CO ≤10ppm as measured by Covita micro smokrlyzer at week 36.

    Time frame: 36 weeks

Other outcomes

  1. Biomarker Evaluation

    Effect of smoking abstinence on levels of cardiac specific biomarkers

    Time frame: 36 weeks

07

Results

Posted Mar 7, 2023
Limitations and caveats
From March 16, 2020-August 10, 2020 study recruitment was halted due to COVID-19.

Participant flow

Participant flow — Overall Study
MilestoneVarenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and Varenicline
Started46474249
Completed36372830
Not completed10101419

Outcome measures

PrimaryNumber of Participants With 7-day Point Prevalence Abstinence at 36 Weeks

7-day point-prevalence abstinence based onno self-reported tobacco use (not even a puff) during the 7 days preceding the assessment and a CO ≤10ppm as measured by Covita micro smokrlyzer at week 36.

Time frame:
36 weeks
Reported as:
Count of participants · Participants
Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks
ParticipantsVarenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and Varenicline
Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks5415
Other pre-specifiedBiomarker Evaluation

Effect of smoking abstinence on levels of cardiac specific biomarkers

Time frame:
36 weeks

Results for this outcome have not been posted.

Adverse events

Collected over 12 weeks--This is the timeframe for the medication related non-serious adverse events as the medication part of the trial was discontinued after 12 weeks. 36 weeks--This is the timeframe for all cause mortality and serious adverse events. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline + Standard of Care0/46 (0%)0/46 (0%)33/46 (71.7%)
Placebo + Standard of Care0/47 (0%)0/47 (0%)30/47 (63.8%)
Positively Smoke Free + Placebo0/42 (0%)0/42 (0%)25/42 (59.5%)
Positively Smoke Free + Varenicline0/49 (0%)0/49 (0%)32/49 (65.3%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventVarenicline + Standard of CarePlacebo + Standard of CarePositively Smoke Free + PlaceboPositively Smoke Free + Varenicline
Increased appetiteGastrointestinal disorders7/467/4713/424/49
Dry mouthGastrointestinal disorders13/466/474/423/49
NauseaGastrointestinal disorders9/466/474/428/49
stiffnessMusculoskeletal and connective tissue disorders2/461/477/421/49
RhinorrheaRespiratory, thoracic and mediastinal disorders6/463/473/428/49
Abnormal dreamsPsychiatric disorders6/466/473/422/49
DizzinessNervous system disorders3/466/471/426/49
HeadacheNervous system disorders4/466/475/424/49
GERDGastrointestinal disorders5/463/472/424/49
Abdominal painGastrointestinal disorders5/460/473/422/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
Mean51.5 ± 10.752.0 ± 8.555.3 ± 8.152.6 ± 10.352.8 ± 9.6
Sex/Gender, Customized
Sex/Gender, Customized(participants)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
Male32302528115
Female1417142166
Transgender00202
Unknown00101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American38434044165
White33028
More than one race512311
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
United States46474249184
Less than 12 years of education
Less than 12 years of education(Participants)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
Count of participants914132359
Employed
Employed(Participants)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
Count of participants16158746
Taking antiretroviral medication
Taking antiretroviral medication(Participants)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
Count of participants42474147177
Cigarettes smoked per day
Cigarettes smoked per day(cigarettes per day)Varenicline and Standard of CarePlacebo and Standard of CarePositively Smoke Free and PlaceboPositively Smoke Free and VareniclineTotal
Mean11.7 ± 6.811.0 ± 5.311.6 ± 7.110.8 ± 5.711.3 ± 6.2

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Maryland Medical Center, Midtown Campus
    Baltimore, Maryland 21210, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 1, 2016

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02460900
Lead sponsor
University of Maryland, Baltimore
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Deanna Kelly (Professor of Psychiatry, University of Maryland, Baltimore) — Principal investigator
First posted
Jun 3, 2015
Start date
Jul 2016
Primary completion
Apr 2021
Completion
Apr 2021
Results posted
Mar 7, 2023
Last update
Mar 13, 2025

Study contacts

Seth Himelhoch, MD, MPH
principal investigator · University of Maryland, Baltimore
Deanna Kelly, PharmD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion